Oncology Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:39
Jan 12
Jan 12
Patent cliffs drive big pharma biotech M&A.
Large pharmaceutical companies facing patent cliffs will look to fill lost top-line revenue by acquiring smaller biotech companies with mid-stage, late-stage, or commercial-stage drugs. We've seen large pharma anticipate this, and the areas of high unmet need where they seek innovation are oncology, inflammatory and immune diseases, and neurology. This should drive continued biotech M&A.
HIGH
19:57
Jan 09
Jan 09
Biotech momentum broadens beyond GLP-1
Biotech momentum is broad and is not just a GLP-1 obesity-drug story. The space is diverse and gains can come from many therapeutic categories, with oncology, rare diseases, cardiovascular, and inflammation among the most topical areas; the trend should continue.
HIGH
16:01
Jan 08
Jan 08
Oncology demand for next big drug.
Oncology is a favored M&A area because every large pharma wants the next $5 billion cancer drug.
MED
About Oncology Investor Commentary
Across the available history and selected sources, Buzzberg tracks Oncology across 1 sources: 3 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: Graig Suvannavejh, Jared Holz, Michael Yee.